Posts Tagged: point of care diagnostics

Xagenic announces $15 million financing round with Series B investors

TORONTO (July 9, 2015) — Xagenic, a molecular diagnostics company developing the lab-free Xagenic X1™ platform for point-of-care use, today announced that it has raised $15 million (CAD). Each of the company's Series B investors has participated in this financing, including Domain Associates, CTI Life Sciences, BDC Capital and the Ontario Capital Growth Corporation. PE Hub, Cantech Letter, Genome Web, Fierce Medical Devices and the Wall Street Journal's Venture Capital Dispatch blog covered this announcement. In June, Xagenic also announced it has acquired ... Read more

Xagenic announces $6 million GAAP partnership for Hepatitis C testing; appoints president and CEO

Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, announced October 15, 2014 that its project in partnership with the University of Toronto was successful in securing funding from Genome Canada under the Genomic Applications Partnership Program (GAPP). The funding, announced by the Honourable Ed Holder, Minister of State (Science and Technology) and Dr. Pierre Meulien, president and CEO of Genome Canada, is part of 12 selected projects under Genome Canada’s Genomic Applications ... Read more

Frost & Sullivan awards Xagenic award for new product innovation leadership

Market research company lauds start-up for developing a breakthrough workflow while dramatically improving point-of-care diagnosis (MOUNTAIN VIEW, Calif) May 20, 2014 — Based on its recent analysis of the point-of-care diagnostics market, Frost & Sullivan recognizes Xagenic Inc. with the 2014 North America Frost & Sullivan Award for New Product Innovation Leadership. Xagenic’s revolutionary product, the Xagenic X1™ system, is a point-of-care platform with intuitive features to provide lab-free molecular diagnostic testing. It is unique as a low-cost, simple, rapid sample-to-answer desktop instrument, ... Read more

MI’s Joel Liederman opens medical device panel at BioTransfer 2014

Joel Liederman, MaRS Innovation's vice-president of Business Development and Commercialization for physical sciences, is attending BioTransfer 2014 on March 18 to chair the Medical Devices Committee. This is the first year that Toronto is hosting the BioTransfer conference. Presenters at the one-day event will discuss biotherapeutics, diagnosis and medical technology. The conference's goal is to share knowledge on current trends in the industry and to stimulate collaboration with private sector companies. As chair, Liederman will open the medical devices committee panel discussion on Tuesday afternoon ... Read more